ACADIA Pharmaceuticals

$48.01
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$1.66 (+3.51%) Today

-$0.96 (-1.96%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell ACAD and other stocks, options, and ETFs commission-free!

About ACAD

ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firms product include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA. The listed name for ACAD is ACADIA Pharmaceuticals Inc. Common Stock.

CEO

Stephen R. Davis

Employees

503

Headquarters

San Diego, California

Founded

1993

Market Cap

8.19B

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

848.59K

High Today

$49.37

Low Today

$47.13

Open Price

$47.34

Volume

992.87K

52 Week High

$58.72

52 Week Low

$30.02

ACAD News

BenzingaFeb 25

ROCE Insights For ACADIA Pharmaceuticals

ACADIA Pharmaceuticals (NASDAQ:ACAD) reported Q4 sales of $121.01 million. Earnings fell to a loss of $67.16 million, resulting in a 21.81% decrease from last q

BenzingaFeb 23

A Preview Of ACADIA Pharmaceuticals's Earnings

On Wednesday, February 24, ACADIA Pharmaceuticals (NASDAQ:ACAD) will release its latest earnings report. Check out Benzinga's preview to understand the implicat

Analyst Ratings

90%

of 20 ratings

Buy

90%

Hold

10%

Sell

ACAD Earnings

-$0.57

-$0.47

-$0.37

-$0.27

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

-$0.47 per share

Actual

-$0.42 per share

Replay Earnings Call